Connor Clark & Lunn Investment Management Ltd. Acquires New Position in Medpace Holdings, Inc. $MEDP

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 110,353 shares of the company’s stock, valued at approximately $58,442,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BOKF NA raised its position in shares of Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after purchasing an additional 20 shares during the period. Valeo Financial Advisors LLC boosted its holdings in Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after buying an additional 21 shares during the period. UMB Bank n.a. boosted its holdings in Medpace by 5.6% in the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after buying an additional 24 shares during the period. Schulhoff & Co. Inc. grew its stake in Medpace by 1.1% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after buying an additional 25 shares in the last quarter. Finally, Balefire LLC grew its stake in Medpace by 6.1% in the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after buying an additional 26 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

NASDAQ MEDP opened at $620.75 on Monday. The stock’s 50-day simple moving average is $550.16 and its two-hundred day simple moving average is $492.03. The company has a market capitalization of $17.33 billion, a price-to-earnings ratio of 36.39, a PEG ratio of 2.77 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same period last year, the business earned $3.10 earnings per share. The business’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In other news, VP Susan E. Burwig sold 7,500 shares of the business’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the sale, the vice president owned 62,984 shares of the company’s stock, valued at approximately $37,790,400. The trade was a 10.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 122,261 shares of company stock valued at $71,729,129. 20.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Barclays set a $600.00 target price on shares of Medpace in a report on Thursday, July 23rd. Robert W. Baird lifted their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and increased their price objective for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $535.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.